NK3 receptors mediate an increase in firing rate of midbrain dopamine neurons of the rat and the guinea pig

Synapse

Volumn 65, Issue 8, 2011, Pages 814-826

  Werkman, Taco R ^a   Mccreary, Andrew C ^b   Kruse, Chris G ^b   Wadman, Wytse J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Chemical Design and Synthesis Unit   (Netherlands)

Author keywords

Extracellular recording; Osanetant; Schizophrenia; Slice preparation; Substantia nigra; Ventral tegmental area

Indexed keywords

AUTORECEPTOR; DOPAMINE; NEUROKININ 3 RECEPTOR; OSANETANT; QUINPIROLE; SENKTIDE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CELL SUBPOPULATION; CONCENTRATION RESPONSE; DOPAMINERGIC NERVE CELL; GUINEA PIG; IN VITRO STUDY; MALE; MESENCEPHALON; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR DENSITY; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM;

ACTION POTENTIALS; ANIMALS; ANTIPSYCHOTIC AGENTS; DOPAMINE; DOPAMINE AGONISTS; ELECTROPHYSIOLOGY; GUINEA PIGS; MALE; MESENCEPHALON; NEURONS; ORGAN CULTURE TECHNIQUES; PEPTIDE FRAGMENTS; PIPERIDINES; RATS; RATS, WISTAR; RECEPTORS, NEUROKININ-3; SPECIES SPECIFICITY; SUBSTANCE P;

EID: 79957799317     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20908     Document Type: Article

References (51)

1. Almeida TA, Rojo J, Nieto PM, Pinto FM, Hernandez M, Martin JD, Candenas ML. 2004. Tachykinins and tachykinin receptors: Structure and activity relationships. Curr Med Chem 11: 2045-2081.
2. Ariens EJ, Simonis AM. 1964a. A molecular basis for drug action. J Pharm Pharmacol 16: 137-157.
3. Ariens EJ, Simonis AM. 1964b. A molecular basis for drug action. The interaction of one or more drugs with different receptors. J Pharm Pharmacol 16: 289-312.
4. Bannon MJ, Whitty CJ. 1995. Neurokinin receptor gene expression in substantia nigra: Localization, regulation, and potential physiological significance. Can J Physiol Pharmacol 73: 866-870.
5. Beaujouan JC, Saffroy M, Torrens Y, Glowinski J. 1997. Potency and selectivity of the tachykinin NK3 receptor antagonist SR 142801. Eur J Pharmacol 319(2-3): 307-316.
6. Beaujouan JC, Torrens Y, Saffroy M, Kemel ML, Glowinski J. 2004. A 25 year adventure in the field of tachykinins. Peptides 25: 339-357.
7. Cameron DL, Wessendorf MW, Williams JT. 1997. A subset of ventral tegmental area neurons is inhibited by dopamine, 5-hydroxytryptamine and opioids. Neuroscience 77: 155-166.
8. Chahl LA. 2006. Tachykinins and neuropsychiatric disorders. Curr Drug Targets 7: 993-1003.
9. Chen LW, Guan ZL, Ding YQ. 1998. Mesencephalic dopaminergic neurons expressing neuromedin K receptor (NK3): A double immunocytochemical study in the rat. Brain Res 780: 150-154.
10. Dawson LA, Cato KJ, Scott C, Watson JM, Wood MD, Foxton R, de la Flor R, Jones GA, Kew JN, Cluderay JE, Southam E, Murkitt GS, Gartlon J, Pemberton DJ, Jones DN, Davies CH, Hagan J. 2008. In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia. Neuropsychopharmacology 33: 1642-1652.
11. Dawson LA, Smith PW. 2010. Therapeutic utility of NK3 receptor antagonists for the treatment of schizophrenia. Curr Pharm Des 16: 344-357.
12. Dietl MM, Palacios JM. 1991. Phylogeny of tachykinin receptor localization in the vertebrate central nervous system: Apparent absence of neurokinin-2 and neurokinin-3 binding sites in the human brain. Brain Res 539: 211-222.
13. Ding YQ, Shigemoto R, Takada M, Ohishi H, Nakanishi S, Mizuno N. 1996. Localization of the neuromedin K receptor (NK3) in the central nervous system of the rat. J Comp Neurol 364: 290-310.
14. Ebner K, Sartori SB, Singewald N. 2009. Tachykinin receptors as therapeutic targets in stress-related disorders. Curr Pharm Des 15: 1647-1674.
15. Emonds-Alt X, Bichon D, Ducoux JP, Heaulme M, Miloux B, Poncelet M, Proietto V, Van Broeck D, Vilain P, Neliat G, et al. 1995. SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptor. Life Sci 56: PL27-PL32.
16. Grace AA, Onn SP. 1989. Morphology and electrophysiological properties of immunocytochemically identified rat dopamine neurons recorded in vitro. J Neurosci 9: 3463-3481.
17. Gueudet C, Santucci V, Soubrie P, Le Fur G. 1999. Blockade of neurokinin3 receptors antagonizes drug-induced population response and depolarization block of midbrain dopamine neurons in guinea pigs. Synapse 33: 71-79.
18. Hainsworth AH, Roper J, Kapoor R, Ashcroft FM. 1991. Identification and electrophysiology of isolated pars compacta neurons from guinea-pig substantia nigra. Neuroscience 43: 81-93.
19. Keegan KD, Woodruff GN, Pinnock RD. 1992. The selective NK3 receptor agonist senktide excites a subpopulation of dopamine-sensitive neurones in the rat substantia nigra pars compacta in vitro. Br J Pharmacol 105: 3-5.
20. Khawaja AM, Rogers DF. 1996. Tachykinins: Receptor to effector. Int J Biochem Cell Biol 28: 721-738.
21. Langlois X, Wintmolders C, te Riele P, Leysen JE, Jurzak M. 2001. Detailed distribution of Neurokinin 3 receptors in the rat, guinea pig and gerbil brain: A comparative autoradiographic study. Neuropharmacology 40: 242-253.
22. Leffler A, Ahlstedt I, Engberg S, Svensson A, Billger M, Oberg L, Bjursell MK, Lindstrom E, von Mentzer B. 2009. Characterization of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and 3. Biochem Pharmacol 77: 1522-1530.
23. Lessard A, Grady EF, Bunnett NW, Pickel VM. 2007. Predominant surface distribution of neurokinin-3 receptors in non-dopaminergic dendrites in the rat substantia nigra and ventral tegmental area. Neuroscience 144: 1393-1408.
24. Maggi CA. 1995. The mammalian tachykinin receptors. Gen Pharmacol 26: 911-944.
25. Malherbe P, Bissantz C, Marcuz A, Kratzeisen C, Zenner MT, Wettstein JG, Ratni H, Riemer C, Spooren W. 2008. Me-talnetant and osanetant interact within overlapping but not identical binding pockets in the human tachykinin neurokinin 3 receptor transmembrane domains. Mol Pharmacol 73: 1736-1750.
26. Malherbe P, Kratzeisen C, Marcuz A, Zenner MT, Nettekoven MH, Ratni H, Wettstein JG, Bissantz C. 2009. Identification of a critical residue in the transmembrane domain 2 of tachykinin neurokinin 3 receptor affecting the dissociation kinetics and antagonism mode of osanetant (SR 142801) and piperidine-based structures. J Med Chem 52: 7103-7112.
27. Marco N, Thirion A, Mons G, Bougault I, Le Fur G, Soubrie P, Steinberg R. 1998. Activation of dopaminergic and cholinergic neurotransmission by tachykinin NK3 receptor stimulation: An in vivo microdialysis approach in guinea pig. Neuropeptides 32: 481-488.
28. Meltzer H, Prus A. 2006. NK3 receptor antagonists for the treatment of schizophrenia. Drug Discov Today Ther Strat 3: 555-560.
29. Meltzer HY, Arvanitis L, Bauer D, Rein W. 2004. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 161: 975-984.
30. Mileusnic D, Lee JM, Magnuson DJ, Hejna MJ, Krause JE, Lorens JB, Lorens SA. 1999. Neurokinin-3 receptor distribution in rat and human brain: An immunohistochemical study. Neuroscience 89: 1269-1290.
31. Nagano M, Saitow F, Haneda E, Konishi S, Hayashi M, Suzuki H. 2006. Distribution and pharmacological characterization of primate NK-1 and NK-3 tachykinin receptors in the central nervous system of the rhesus monkey. Br J Pharmacol 147: 316-323.
32. Nalivaiko E, Michaud JC, Soubrie P, Le Fur G, Feltz P. 1997. Tachykinin neurokinin-1 and neurokinin-3 receptor-mediated responses in guinea-pig substantia nigra: An in vitro electrophysiological study. Neuroscience 78: 745-757.
33. Nguyen-Le XK, Nguyen QT, Gobeil F, Pheng LH, Emonds-Alt X, Breliere JC, Regoli D. 1996. Pharmacological characterization of SR 142801: A new non-peptide antagonist of the neurokinin NK-3 receptor. Pharmacology 52: 283-291.
34. Overton P, Elliott PJ, Hagan RM, Clark D. 1992. Neurokinin agonists differentially affect A9 and A10 dopamine cells in the rat. Eur J Pharmacol 213: 165-166.
35. Patacchini R, Bartho L, Holzer P, Maggi CA. 1995. Activity of SR 142801 at peripheral tachykinin receptors. Eur J Pharmacol 278: 17-25.
36. Pennefather JN, Lecci A, Candenas ML, Patak E, Pinto FM, Maggi CA. 2004. Tachykinins and tachykinin receptors: A growing family. Life Sci 74: 1445-1463.
37. Pickar D. 1995. Prospects for pharmacotherapy of schizophrenia. Lancet 345: 557-562.
38. Raffa RB. 1998. Possible role(s) of neurokinins in CNS development and neurodegenerative or other disorders. Neurosci Biobehav Rev 22: 789-813.
39. Richelson E. 1999. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 60( Suppl 10): 5-14.
40. Rigby M, O'Donnell R, Rupniak NM. 2005. Species differences in tachykinin receptor distribution: further evidence that the substance P (NK1) receptor predominates in human brain. J Comp Neurol 490: 335-353.
41. Saffroy M, Torrens Y, Glowinski J, Beaujouan JC. 2003. Autoradiographic distribution of tachykinin NK2 binding sites in the rat brain: comparison with NK1 and NK3 binding sites. Neuroscience 116: 761-773.
42. Satake H, Kawada T. 2006. Overview of the primary structure, tissue-distribution, and functions of tachykinins and their receptors. Curr Drug Targets 7: 963-974.
43. Seabrook GR, Bowery BJ, Hill RG. 1995. Pharmacology of tachykinin receptors on neurones in the ventral tegmental area of rat brain slices. Eur J Pharmacol 273(1-2): 113-119.
44. Severini C, Improta G, Falconieri-Erspamer G, Salvadori S, Erspamer V. 2002. The tachykinin peptide family. Pharmacol Rev 54: 285-322.
45. Shi WX. 2009. Electrophysiological characteristics of dopamine neurons: A 35-year update. J Neural Transm Suppl 73: 103-119.
46. Smith PW, Dawson LA. 2008. Neurokinin 3 (NK3) receptor modulators for the treatment of psychiatric disorders. Recent Patents CNS Drug Discov 3: 1-15.
47. Spooren W, Riemer C, Meltzer H. 2005. Opinion: NK3 receptor antagonists: The next generation of antipsychotics? Nat Rev Drug Discov 4: 967-975.
48. Tian G, Wilkins D, Scott CW. 2007. Neurokinin-3 receptor-specific antagonists talnetant and osanetant show distinct mode of action in cellular Ca2+ mobilization but display similar binding kinetics and identical mechanism of binding in ligand cross-competition. Mol Pharmacol 71: 902-911.
49. Werkman TR, Kruse CG, Nievelstein H, Long SK, Wadman WJ. 2001. In vitro modulation of the firing rate of dopamine neurons in the rat substantia nigra pars compacta and the ventral tegmental area by antipsychotic drugs. Neuropharmacology 40: 927-936.
50. Whitty CJ, Walker PD, Goebel DJ, Poosch MS, Bannon MJ. 1995. Quantitation, cellular localization and regulation of neurokinin receptor gene expression within the rat substantia nigra. Neuroscience 64: 419-425.
51. Yip J, Chahl LA. 2001. Localization of NK1 and NK3 receptors in guinea-pig brain. Regul Pept 98(1-2): 55-62.